CIAM
AVBP icon

Caitong International Asset Management’s ArriVent BioPharma AVBP Stock Holding History

Caitong International Asset Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$715 Sell
31
-776
-96% -$17.5K ﹤0.01% 1537
2025
Q4 		$16.2K Buy
+807
New +$16.8K ﹤0.01% 1037
2025
Q2 		– Sell
-383
Closed -$7.08K – 2565
2025
Q1 		$7.08K Buy
383
+370
+2,846% +$9.05K 0.01% 941
2024
Q4 		$346 Buy
+13
New +$373 ﹤0.01% 1517

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Caitong International Asset Management's AVBP Position: Q1 2026 in Review

Caitong International Asset Management reduced its ArriVent BioPharma (AVBP) stake by 96% in Q1 2026, selling an estimated $17.5K and leaving 31 shares worth $715. The position accounts for ﹤0.01% of the portfolio, ranked #1537.

Caitong International Asset Management first reported a position in AVBP in Q4 2024 and has held it in 4 quarters since. The position peaked at $16.2K in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Caitong International Asset Management held 31 shares of ArriVent BioPharma worth $715 as of Q1 2026.
  • Caitong International Asset Management sold 776 ArriVent BioPharma shares in Q1 2026, an estimated $17.5K.
  • ArriVent BioPharma made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #1537 holding.
  • Caitong International Asset Management first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 4 quarters since.
  • Caitong International Asset Management's ArriVent BioPharma position peaked at $16.2K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.